Mergers & AcquisitionsBy The Online Investor Staff, updated Sat., Sep. 19, 7:17 AM
|This Slide: #78 of 100|
Slide #78. Northwest Biotherapeutics — Flaskworks
Northwest Biotherapeutics (NWBO)
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax.
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers. Co. has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The DCVax technology is embodied in several distinct product lines. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers which are considered inoperable and cannot be surgically removed.
Open the NWBO Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite